Introduction
In mainstream thymopoiesis, positive selection of CD4 ϩ CD8 ϩ cells to the CD8 lineage minimally requires the engagement of the TCR with MHC class I-peptide expressed on thymic epithelial cells. The precise role of peptide, however, is still unclear with current theories being that a variety of self peptides, not exclusively related to the antigenic peptide, may be involved in the positive selection of a particular T cell (1, 2) . This is not unexpected given that the TCR is not exquisitely specific, being able to recognize a variety of MHCpeptide ligands, albeit with varying affinities (3, 4) . In support of this, our model for positive selection using adult stroma and P14 TCR transgenic mice specific to the lymphocytic choriomeningitis virus (LCMV) has shown positive selection occurring in the absence of nominal peptide-presumably by endogenous peptide(s) (5) . These cells, fewer by comparison Correspondence to: A. Chidgey Transmitting editor: H. R. MacDonald Received 8 December 1997, accepted 31 March 1998 to selection occurring in the presence of low (10 -10 M) concentrations of the p33 peptide, were phenotypically and functionally mature, exhibiting cytotoxicity and proliferation when challenged with the nominal p33 peptide. T cells are able to interact via their TCR to a variety of MHC-peptide ligands, with peptides ranging from single amino acid variations of the agonist peptide to peptides showing little homology (3, 6) . These peptide variants, often termed altered peptide ligands, induce only partial activation of the T cell and can have a varied impact upon peripheral T cell response (7, 8) . How such peptides differentially affect the TCR interaction in mature T cells is still unclear and even more so in immature thymocytes. It may be of a qualitative nature with agonist and antagonist peptides inducing different downstream signalling events in mature T cells (8) (9) (10) . It may be more quantitative, with antagonist peptides having faster dissociation rates than agonist peptides (11, 12) , which in turn affects their ability to induce a T cell response. Nevertheless such antagonist peptides are capable of inducing and blocking both positive and negative selection (13) (14) (15) (16) . Thus, the influence of antagonist peptides or altered peptide ligands on thymic selection remains inconclusive.
Regardless of the role of peptide, the TCR affinity and the avidity of T cell-thymic epithelial cell interactions are likely to be important in determining whether a cell will undergo positive or negative selection. Herein lies the influence of accessory molecules such as the co-receptor, among others, which may influence thymic selection. The exact role of the CD8 co-receptor in positive selection of MHC class I-restricted T cells, however, has yet to be clearly defined; whether it merely contributes to the avidity of the TCR-MHC-peptide interactions or whether its importance lies in intracellular signalling, or both. In the absence of the CD8α chain, functional cytotoxic T cells do not develop (17, 18) although more recently it has been shown that positive selection of CD8 T cells can be rescued in CD8α knockout mice transgenic for the OT-1 TCR and for P14 TCR respectively, by increasing the affinity of the TCR-MHC-peptide interactions (19, 20) . The CD8β chain improves the efficiency of positive selection (21-23) though is not obligatory for the antigen-specific response in mature CD8 cytotoxic T cells (21, 24) . Whilst the co-receptor increases the affinity of the TCR-MHC-peptide interactions with CD8αβ heterodimers being more efficient in this respect than CD8αα homodimers (25) possibly due to a faster 'on' rate (26) , its configuration is also thought to be subject to modulation through TCR-ligand interactions (27) .
This apparent flexibility of co-receptor usage may be important in the developmental fate of the T cell. We have shown recently that during the process of positive selection, T cells can modify the threshold for positive selection by altering the expression of the CD8 co-receptor both quantitatively and qualitatively in response to high but non-deleting concentrations of agonist peptide (5) . The down-regulation at the level of the entire co-receptor or just the CD8β chain may allow a broader range of TCR affinities for a particular clonotype to be positively selected. It may of course also allow the escape of thymic tolerance of potentially autoreactive T cells.
This present paper addresses further the down-regulation of the CD8 co-receptor and CD8β chain in particular during positive selection, both in terms of the functional efficiency of these subsets and the existence of similar co-receptor modulation in the presence of peptide variants of both agonist and antagonist nature. We have found that reduced signalling interactions as in the case with low concentrations of nominal agonist peptide and intermediate to low concentrations of peptide variants will positively select CD8 hi heterodimers (CD8αβ) in this LCMV transgenic system. However, strong signalling interactions as in the case with intermediate to high concentrations of the nominal agonist and moderate agonist variant can induce co-receptor down-modulation, with the resultant positively selected cells being of the TCR hi CD8αβ int , TCR hi CD8α homodimer or TCR hi CD8 -phenotype. These cells do not up-regulate their CD8β chain or CD8 co-receptor upon further stimulation and hence represent a potentially autoreactive but low respondant population of cells that, within a normal healthy environment, would not be activated. These data are consistent with the proposal that the overall strength of signalling determines whether a cell will undergo positive or negative selection, or die by neglect in the absence of a strong enough signal, rather than the inherent agonistic or antagonistic properties of the selecting peptide.
Methods

Mice
P14 αβ TCR transgenic mice specific to the LCMV, H-2D b restricted (28) , were bred onto a non-selecting background (H-2 d ) and were maintained in the Monash University animal house. Ly 5.1 congenic C57Bl6 mice were maintained in the Monash University animal house.
Peptides
The nominal LCMV agonist peptide, p33 (amino acids 33-41; KAVYNFATM), has the original cysteine at anchor position 41 in the wild-type LCMV peptide replaced with a methionine to prevent dimer formation. The peptides listed in Table 1 were a kind gift from Pamela Ohashi. All peptides were synthesized at the Amgen Institute (Boulder, CO) by a solid-phase method using the Fmoc/tBubased protocol on an ABI-431 instrument. The crude products were purified on a reverse-phase preparative HPLC column (C4; Vydac, Hesperia, CA).
Co-cultures
The co-cultures were set up essentially as described in Chidgey and Boyd (5) . Briefly, thymic stromal cells from Ly 5.1 congenic C57Bl6 mice (H-2 b ) were freshly prepared by gentle enzymic digestion (0.15% collagenase/0.1% DNase; Boehringer Mannheim, Mannheim, Germany) of lymphocytedepleted thymuses and enriched to a lymphocyte to stromal cell ratio of~2:1 by elutriation. All cells were resuspended in Clicks medium (Gibco/BRL, Gaithersburg, MD) supplemented with 10% heat-inactivated FCS (Gibco/BRL), 2m M L-glutamine (Flow, Irvine, UK), 0.05% benzyl penicillia (CSL, Melbourne, Australia), 0.05% streptomycin (Sigma, St Louis, MO) and 5ϫ10 -5 M 2-mercaptoethanol (Sigma) at a concentration of 6.7ϫ10 5 cells/ml, and pulsed with peptide. E17 thymocytes from P14 αβ TCR transgenic mice (specific to the lymphocytic choriomeningitis virus; H-2 b restricted) (28) on a non-selecting H-2 d background were prepared at a concentration of 3.4ϫ10 6 cells/ml and mixed with the stromal cells at a ratio of 5:1. Cell suspensions were co-cultured as hanging drops in inverted Terasaki plates at 37°C, 5% CO 2 and harvested generally at day 4. P14 transgenic thymocytes were distinguished from stromal-associated lymphocytes by the expression of Ly 5.2. Cells were generally stained with Ly 5.2-FITC (PharMingen, San Diego, CA), CD8-Biotin/TriColor (PharMingen) and CD4-phycoerythrin (PE; PharMingen) and analysed by flow cytometry.
Flow cytometry
Cells were analysed using a FACScan flow cytometer (BectonDickinson, Mountain View, CA) and Lysys II software (Becton Dickinson). Cells were sorted on a FACStar Plus (Becton Dickinson) using Lysys II software. Dead cells were excluded by a cell viability gate using forward versus side scatter. The FACS machines were calibrated with total thymocytes unstained and stained with Ly5.2-FITC, CD4-PE and CD8-biotin/TriColor.
Stimulation assay
Co-cultures of P14 H-2 d transgenic thymocytes and freshly purified H-2 b stroma in the presence or absence of peptide were prepared and analysed as described above; however, the purified stroma was irradiated at 3000 rad prior to coculture to prevent proliferation of stroma-associated lymphocytes. At day 4 the cells were counted and percentage of viable transgenic cells determined by flow cytometry using a FACScan (Becton Dickinson). Alternatively, cells were stained with CD8α-PE (PharMingen) and CD8β-biotin (PharMingen) followed by streptavidin-FITC (PharMingen), and sorted on a FACStar Plus (Becton Dickinson). Dead cells were gated out using a FSC/SSC-defined cell viability gate. The cells were placed into round-bottom wells of a 96-well plate (5ϫ10 4 transgenic cells/well) with IL-2 (25 units) and 5ϫ10 5 irradiated (3000 rad) H-2 b splenocytes which had been pre-pulsed with 10 -5 M p33 peptide, unless specified differently, for a period of 48 h.
Functional assays
For the proliferation assay, [ 3 H]thymidine was added 14 h prior to harvesting and incorporated radioactivity measured on a β-counter. RNA extraction and mRNA detection by PCR RNA was extracted essentially by the method described in Chomczynski and Sacchi (32) . In brief,~10 4 to 10 5 CD8αβ, CD8αα, CD8 -cells were washed in HBSS, pelleted in Eppendorf tubes and resuspended in GTC solution (4 M guanidinium isothiocyanate, 0.25m M tri-sodium citrate, 0.1 M β-mercaptoethanol and 0.5% sodium lauryl sarkosinate). This was followed by the addition of acidic phenol then chloroform:isoamly alcohol and incubated for 30 min on ice. After centrifuging, RNA was precipitated using isopropanol, washed in 70% ethanol and used for single-stranded cDNA synthesis using an oligo(dT) 15 primer. The cDNA was used in PCR amplification with oligonucleotides recognizing CD8β sequences (33) . The specific CD8β primers used were 5Ј-CAAGATGCAGCCATGGCTCT-3Ј and 5Ј-CGCACACAGTAAA-AGTAGAC-3Ј. Amplification was carried out for 30 cycles with an annealing temperature of 55°C. The PCR products were analysed by electrophoresis on a 1% agarose gel.
Results
CD8 ϩ positively selected cells show an inverse correlation between the concentration of agonist peptide and their functional efficiency
Using an adult stromal cell suspension model for in vitro positive selection we have previously found that transgenic TCR hi CD4 -CD8αβ hi cells can be selected by endogenous peptide(s) expressed on thymic stromal cells (5, 34) . These cells can proliferate and specifically lyse target cells loaded with the nominal p33 peptide. More efficient positive selection, in terms of absolute numbers of TCR hi CD8αβ hi T cells, occurred in the presence of low concentrations of p33 (10 -10 M); these peptide-selected cells were also able to efficiently lyse p33-loaded target cells (5) . However, in the presence of higher concentrations of nominal peptide (10 -8 to 10 -5 M), fewer CD8 ϩ cells were selected and they lysed p33-loaded target cells with decreased efficiency (Fig. 1) . This was also reflected in their reduced ability to proliferate when challenged with p33-loaded antigen-presenting cells (APC) (Fig. 2) . This compromised functional efficiency correlated with increasing concentrations of agonist peptide in the co-cultures. In addition there was a progressive shift from CD8αβ to CD8αα to CD8 -cells.
When subsets of CD8 ϩ cells induced in the positive selection co-cultures were sorted and stimulated with fresh APC loaded with the nominal agonist peptide, p33 (10 -5 M), the CD8αβ cells clearly showed a greater proliferative capacity in comparison to the CD8αα subset (Fig. 3A) ; this was true over several concentrations of peptide loaded onto the APC (Fig. 3B) . Similarly, TCR int/hi CD4 -CD8 -cells consistently gave a similar or lower proliferative response than the CD8αα cells (Fig. 3A) .
The CD8β chain is down-regulated at the level of the mRNA and is not reversible upon further stimulation with the nominal peptide
We have previously shown that the CD8αα and CD8 -cells were derived from CD4 ϩ CD8αβ ϩ precursors (5). To determine whether this down-regulation of the CD8 co-receptor chain was solely at the level of surface expression, CD8 -and CD8αα cells were sorted post-positive selection and mRNA purified. There was clearly no CD8β message (Fig. 4) . Furthermore the CD8 -and CD8αα T cells do not up-regulate their CD8β chain surface expression after being stimulated with p33-loaded fresh APC (data not shown).
Not all LCMV single amino acid peptide variants can positively select Peptide variants of the nominal agonist peptide were tested for their ability to increase the efficiency of positive selection. These peptides have been described using various in vitro assays as having agonist or antagonist properties. The peptide variant A4Y (KAVANFATM) is a moderate agonist with no antagonist properties (29) , S4Y (KAVSNFATM) is a strong antagonist with no agonist properties (29, 30) , C4Y (KAVCNF-ATM) is a moderate antagonist (Pam Ohashi, pers. commun.) and G4Y (KAVGNFATM) is a weak antagonist with no agonist properties (30, 31) . The H-2 b binding adenovirus peptide (SGPSNTPPEI) (29) was used as a negative control.
The A4Y moderate agonist variant was able to induce positive selection to a greater degree compared to the nominal p33 peptide, consistent with the findings of Sebzda et al. (29) . In terms of absolute cell numbers (Fig. 5A ) the A4Y peptide at 10 -7 M was able to induce a 2-to 3-fold increase in CD8 hi cell number above background levels and a 1.5-fold increase above that induced by the nominal p33 agonist peptide. At this concentration the nominal peptide induces some negative selection, particularly in the early stages of co-culture, as illustrated in kinetics studies published in a previous paper (5) . In the presence of antagonist peptides, only C4Y substantially increased the efficiency of positive selection at 10 -7 M, inducing a 3-fold increase in CD8 hi cell numbers above background. The S4Y and G4Y variants had no significant effect on positive selection nor had the unrelated control peptide AV. Interestingly, the strong antagonist S4Y peptide variant did not antagonize the TCR interactions involving endogenous peptide, with positive selection with this peptide (21%) being similar to co-cultures containing no exogenous peptide; under the same conditions A4Y peptide increased selection to~30% (Fig. 5B) .
CD8 T cells selected in the presence of antagonist peptide variants do not down-regulate their CD8β chain CD4 ϩ CD8αβ ϩ transgenic T cells co-cultured with H-2 b expressing fresh thymic stromal cells loaded with high but non-deleting concentrations of nominal peptide (10 -7 M) induce the positive selection of predominantly CD8αα hi cells (Fig. 6) . The A4Y agonist peptide variant at the same concentration induced a similar but reduced population of CD8αα hi cells. Also present was a significantly greater population of CD8αβ int cells: 13% compared to 3% in the presence of the nominal p33 peptide and fewer CD8 -cells: 38% compared to 51%, consistent with the reduced agonist properties of this peptide variant (data not shown).
The C4Y antagonist peptide at 10 -7 M induced the positive selection of predominantly CD8αβ hi T cells which reflects its reduced signalling properties compared to the agonist peptides. In the presence of the S4Y and G4Y antagonist peptide variants and the unrelated adenovirus control peptide AV, which did not enhance positive selection, cells of the CD8αβ phenotype were found at similar levels to that found in co-cultures containing no exogenous peptide. These results are consistent with our model for positive selection describing the quantitative and qualitative down-modulation of the CD8 co-receptor with increasing avidity interactions/signalling within the window of positive selection (5). 
Functional capacity of CD8 ϩ T cells selected in the presence of LCMV peptide variants
The proliferative and cytolytic capacities of cells selected in the presence of LCMV peptide variants when further challenged with fresh APC loaded with the nominal p33 peptide are shown in Fig. 7(A and B) . Cells selected in the absence of exogenous peptide or the presence of low concentrations of the nominal peptide, predominantly of the CD8αβ phenotype, are able to efficiently and specifically lyse p33-loaded (10 -5 M) target cells and proliferate in response to p33-loaded (10 -5 M) fresh APC. CD8 ϩ T cells selected in the presence of the p33 peptide at relatively high concentrations (10 -7 M), which are predominantly of the CD8αα hi cells, show a much reduced capacity, cell for cell, to specifically lyse target cells and proliferate. In comparison CD8 ϩ T cells selected in the presence of the LCMV agonist peptide variant A4Y are better able to specifically lyse target cells, however not as efficiently as those selected at low concentrations of nominal peptide (10 -10 M) or by the endogenous peptide. Presumably this is due to the greater numbers of CD8αβ int cells selected with this peptide which appear to have a greater functional capacity than the CD8αα hi cells.
The predominantly CD8αβ cells selected in the presence of the moderate antagonist peptide variant C4Y show a functional capacity similar to those cells selected in the presence of low concentrations of nominal peptide (10 -10 M) or endogenous peptide, both in terms of specific lysis and proliferation.
Discussion
We have found previously that positive selection of TCR hi CD8 hi T cells from TCR transgenic mice specific to the nominal LCMV agonist peptide, p33, can occur in the presence of endogenous peptide(s), albeit inefficiently. This is consistent with recent publications (1,2) suggesting that peptides not necessarily related to the nominal peptide are able to positively select T cells. The efficiency of positive selection, however, could be increased in the presence of low concentrations (10 -10 M) of the nominal peptide, as reflected by the increased numbers of TCR hi CD4 -CD8αβ hi T cells induced (5, 35) . Cells selected in the presence of high but non-deleting doses of agonist peptide were shown to be predominantly of the TCR hi CD8αα hi and TCR hi CD8 -phenotype, these cells having escaped deletion by down-regulating their CD8β chain or entire CD8 co-receptor (5) .
The small population of cells selected by endogenous peptide or low concentrations of the nominal antigenic peptide p33 (10 -10 M) were functionally responsive both in terms of proliferation when challenged with APC loaded with p33 (10 -5 M) and in their capacity to specifically lyse p33-loaded target cells. In the presence of increasing concentrations of the p33 peptide during the process of positive selection, the positively selected T cells become correspondingly less functionally efficient. This is most likely due to the increased presence of positively selected CD8 -and CD8αα cells which, by modulating their co-receptor, were able to escape deletion. This was more apparent when these cells were sorted into individual subsets post co-culture with the CD8 -and CD8αα phenotypes showing reduced proliferative capacity in comparison to CD8αβ cells. In these subsets the CD8β chain was down-regulated at the level of the mRNA and was not reversed when activated with fresh APC loaded with the nominal p33 peptide. This reduced functional capacity of CD8αα T cells was consistent over a range of peptide concentrations presented by APC. Although they did not reach the functional capacity of CD8αβ T cells when challenged with APC loaded with high concentrations (10 -5 M) of p33, CD8αα T cells may have important relevance in autoimmune disease states when antigen is presented in abnormally high concentrations, enough to activate these normally low responsive T cells. The correlation of reduced functional efficiency with an increased percentage of cells of the CD8 -and CD8αα phenotype is consistent with the findings that CD8α homodimers bind the MHC with lower affinity than CD8αβ heterodimers (25, 26) .
Given the controversial role of agonist and antagonist peptide variants in positive selection, we investigated their ability to positively select in the LCMV system and their influence on CD8 co-receptor and CD8β chain down-modulation. The peptide variant A4Y has a single alanine substitution at position 4, which is thought to effect a TCR contact residue and has been described as having moderate agonist characteristics and no antagonist properties (29) . Positive selection was enhanced in the presence of A4Y (10 -7 M) with a 2-to 3-fold increase in TCR hi CD8 hi T cells compared to those selected in the absence of exogenous peptide, consistent with the findings of Sebzda et al. (29) . This was above that of the nominal p33 peptide at the same concentration, which enhanced TCR hi CD8 hi cell numbers only by~1.5-fold, most likely because the p33 peptide at this concentration also induces negative selection. CD8 T cells selected in the presence of A4Y are functional both in terms of proliferation and cytotoxicity when challenged with the 10 -5 M nominal peptide p33. They do, however, show a slightly reduced cytolytic capacity compared to those cells selected in the presence of low concentrations of the agonist peptide (10 -10 M) or endogenous peptide. This illustrates the impact peptide variants can have on different T cell effector functions, consistent with previous findings (7, 8) . Regardless, the T cells selected in the presence of A4Y have a greater functional efficiency in comparison to those cells selected in the presence of similar concentrations of the nominal p33 peptide (10 -7 M) . This difference in functional capacity correlates with the phenotype of the CD8 cells positively selected. The A4Y peptide was found to induce down-modulation of the CD8 co-receptor and CD8β chain, as with the nominal peptide, but to a lesser degree. We found an increased percentage of CD8αβ int cells selected in the presence of this moderate agonist. Also the ratio of CD8αα hi to CD8αβ hi cells was less in the presence of A4Y in comparison to cells selected in the presence of the nominal p33 peptide at the same concentration (10 -7 M), these being predominantly CD8αα or CD8 -cells. Thus the increased presence of CD8αβ int cells appears to improve the functional capacity of the selected T cells compared to CD8αα hi cells but not to the same degree as CD8αβ hi cells.
Positive selection was also enhanced in the presence of the moderate antagonist peptide C4Y which has a single cysteine substitution at position 4. The T cells selected were predominantly of the CD8αβ hi phenotype and showed strong functional responsiveness. This is not surprising in the light of evidence that antagonist peptides have faster dissociation rates than agonist peptides (11) . The overall reduced level of signalling produced by this TCR-MHC-antagonist peptide interaction does not appear to impact upon the modification of the co-receptors as do the stronger TCR-MHC-agonist peptide interactions. Whether this is due primarily to the reduced avidity of the interactions and subsequent reduced strength of overall signalling, to an alteration in the signalling pathway itself due to properties of the antagonist peptide or due to conformation changes induced in the TCR has not yet been determined. However, the outcome is consistent with our model suggesting that T cells, in response to the strength of their TCR-ligand interactions occurring within the window of positive selection, can modulate their co-receptors to avoid deletion. In the case of this antagonist peptide, the strength of signalling was not great enough to induce deletion nor down-modulation of the CD8 co-receptor or CD8β chain. The other peptide variants tested, S4Y, a strong antagonist and G4Y, a weak antagonist, did not show any significant influence on positive selection. Interestingly the strong antagonist S4Y did not significantly reduce background selection, with similar CD8 cell numbers selected as those in the co-cultures containing no exogenous peptide. This may be due to the endogenous peptide having a greater affinity to the MHC than S4Y; it may be due to the degradation of S4Y in culture with some CD4 ϩ CD8 ϩ cells not coming into contact with this peptide or the S4Y peptide may have induced incomplete TCR signalling which did induce some positive selection but was not great enough to enhance positive selection beyond that of background levels. An alternative possibility is that the CD4 ϩ CD8 ϩ cells which express multiple TCR may be exposed to a number of TCR-peptide-MHC interactions within the window of positive selection and it is the sum of these interactions/signals which determines the outcome of whether a cell will be positively selected, as suggested in a review by Williams et al. (36) .
Effectively our data suggest that it is not the agonist or antagonist nature of a peptide per se but the overall strength of signalling that determines whether a cell will be positively or negatively selected, or die by neglect. Furthermore, the agonist/antagonist properties of peptides defined at the level of affecting mature T cell function do not unequivocally predict their effect on positive/negative selection. Some antagonist peptides might inhibit T cell function at the level of MHC competition and thus are unlikely to directly affect positive selection, whereas other antagonists might negatively signal through the TCR-these could influence positive selection. The varied results found in different TCR transgenic systems can be reconciled by the avidity model for positive selection. In the LCMV TCR transgenic model, low concentrations of nominal peptide and of certain peptide variants both of an agonist and antagonist nature induce low signalling/low avidity interactions and result in positive selection. High concentrations of nominal peptide induce strong signalling/high avidity interactions and result in negative selection. In the F5 TCR transgenic model, it was found that strong antagonist peptides were able to block negative selection (16) . This suggests that the antagonist peptide used was acting at the level of the MHC-peptide ligand, blocking any signalling through the TCR, as by definition they block activation of mature cells in the periphery. The antagonist peptides that were able to induce positive selection in OT-1 TCR transgenic mice specific to the OVA peptide, consisted of a mixture of antagonist and partial agonists (13) . The strong antagonist used may be acting at the level of downstream TCR signalling by transducing only a partial signal (8, 9) or a similar effect may result from a fast on-off rate in binding to the MHC or TCR (11, 12) . The end result would be a low signalling/reduced avidity interaction, hence inducing positive selection. The nominal agonist peptide in this system delivered only a deleting signal even at low concentrations (37) , presumably due to the strength of signalling and higher affinity TCR compared to that in the LCMV system. A recent paper by Girao et al. (38) has suggested that only weak agonist peptides could induce the positive selection of functional CD8 ϩ cells in fetal thymic organ cultures from P14 TCR transgenic mice on a TAP-1-/-background. In their system high concentrations of peptide did induce some positive selection of CD8 ϩ cells; however, they suggest that these cells were not functional due to some partial negative selection. We would suggest that their results are consistent with our data, that high but non-deleting concentrations of agonist peptide do positively select cells but induce the down-modulation of the CD8 co-receptor and/or CD8β chain which translates into reduced functional capacity of these T cells. These latter two alternatives need to be tested in their system.
Thus it is the sum of the TCR-ligand interactions and other co-stimulatory molecules which we believe is the determining factor for positive selection rather than the intrinsic properties of an agonist or antagonist peptide. This is supported by the ability of a T cell to alter its CD8 co-receptor expression to avoid deletion by reducing the overall signalling strength of the TCR-ligand interaction. These interactions, important in determining the fate of a developing T cell, are optimal in the presence of peptides specific to the TCR, with particular peptide variants similarly able to induce positive selection. Cortical epithelial cells in the thymus are exposed to a vast array of self peptides. During positive selection, TCR on the developing thymocyte may bind to a selection of peptide variants, inducing varying degrees of signalling through the TCR. The overall signalling over a period of time (avidity) will induce either negative selection if the signal is above a particular threshold, as in the presence of high concentrations of agonist peptide, or positive selection in the presence of reduced signal interactions, such as that in the presence of some moderate agonists and antagonists. Positive selection with CD8 co-receptor down-modulation or CD8β chain downmodulation occurs in the presence of relatively high but nondeleting signalling interactions as in the case of intermediate concentrations of peptides of an agonist nature. Effectively this would allow the survival of T cells with a broader range of affinities. Important to this model but as yet undefined is the influence of co-stimulatory molecules expressed on thymic epithelial cells.
Clearly the cellular and molecular interactions occurring during positive selection are crucial to the balance and maintenance of a healthy broad spectrum yet non-autoreactive repertoire of T cells, a mechanism which possibly breaks down in states of defective presentation or other thymic abnormalities which occur in some autoimmune diseases (39, 40) .
